SynthesisJournal of clinical oncology : official journal of the American Society of Clinical Oncology2021
Development and Validation of a Tool Integrating the 21-Gene Recurrence Score and Clinical-Pathological Features to Individualize Prognosis and Prediction of Chemotherapy Benefit in Early Breast Cancer.
Synthesis in Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 87 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
87 citing papers in PubMed, 2 syntheses or guidelines pooled it, 142 citations in OpenAlex.
- Clinical and Genomic Risk for Late Breast Cancer Recurrence and Survival.NEJM evidence · 2024Pooled it
- Development and internal-external validation of statistical and machine learning models for breast cancer prognostication: cohort study.BMJ (Clinical research ed.) · 2023Pooled it
- Prognostic and predictive performance of PREDICT 2.1, PREDICT v3, and RSClin in node-negative early breast cancer: a TEAM pathology substudy.Breast cancer research and treatment · 2026Trial
- CDKPredict: a clinicogenomic model for risk-adapted therapeutic intervention in breast cancer.Research square · 2026Article
- Development and validation of a machine learning clinicogenomic model to improve prognostic stratification in ER-positive/HER2-negative early breast cancer.Breast cancer research : BCR · 2026Article
- Impact of Oncotype DX risk categorization and receipt of chemotherapy on survival outcomes among patients with small node-negative HR+ breast cancer.The oncologist · 2026Article
- mRNA and protein expression of fetal insulin receptor in breast cancer cell lines and tissues.Breast cancer research and treatment · 2026Article
- Article
- Genomic Classification to Predict Survival in Metastatic Prostate Cancer: Development of Somatic Tumor Risk Assessment for Overall Survival-Prostate.JCO precision oncology · 2026Article
- Development and validation of a nomogram to assess recurrence risk in young patients with breast cancer based on preoperative serum tumor markers.Gland surgery · 2026Article
- User Perspectives on a Clinical Decision Tool to Support Individualized Exercise Prescriptions for Breast Cancer Survivors Not Meeting Exercise Guidelines: Cross-Sectional Survey.JMIR formative research · 2026Article
- Article
- Development and Validation of a Multimodal Clinical, Pathologic, and Genomic Model for Breast Cancer Recurrence.medRxiv : the preprint server for health sciences · 2026Article
- Risk of late recurrence of colorectal and breast cancer among older long-term cancer survivors.JNCI cancer spectrum · 2026Article
- Accessible Clinical Tool for Prognosis and Chemotherapy Prediction in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer in Diverse and Low-Resource Settings.JCO global oncology · 2026Article
- Transfer Learning and Machine Learning for Training Five-Year Survival Prognostic Models in Early Breast Cancer: Development and Validation Study.Journal of medical Internet research · 2026Article
- Balancing global standards and regional nuances in breast cancer care: the role of guidelines, clinical research, precision medicine, and artificial intelligence in advancing quality of care for patients worldwide.Cancer biology & medicine · 2026Article
- Article
- Benchmarking large language models for predictive modeling in biomedical research with a focus on reproductive health.Cell reports. Medicine · 2026Article
- Machine Learning-Based Prediction of Distant Recurrence Risk and Ribociclib Treatment Effect in HR+/HER2- Early Breast Cancer Using Real-World and NATALEE Data.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
27 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Commented on by
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
purposeThe 21-gene recurrence score (RS) is prognostic for distant recurrence (DR) and predictive for chemotherapy benefit in early breast cancer, whereas clinical-pathological factors are only prognostic. Integration of genomic and clinical features offers the potential to guide adjuvant chemotherapy use with greater precision.
methodsWe developed a new tool (RSClin) that integrates RS with tumor grade, tumor size, and age using a patient-specific meta-analysis including 10,004 women with hormone receptor-positive, human epidermal growth factor receptor 2-negative, and node-negative breast cancer who received endocrine therapy alone in the B-14 (n = 577) and TAILORx (n = 4,854) trials or plus chemotherapy in TAILORx (n = 4,573). Cox models for RSClin were compared with RS alone and clinical-pathological features alone using likelihood ratio tests. RSClin estimates of DR used a baseline risk with TAILORx event rates to reflect current medical practice. A patient-specific estimator of absolute chemotherapy benefit was computed using individualized relative chemotherapy effect from the randomized TAILORx and B-20 trials. External validation of risk estimation was performed by comparing RSClin estimated risk and observed risk in 1,098 women in the Clalit registry.
resultsRSClin provides more prognostic information (likelihood ratio χ
conclusionThe RSClin tool integrates clinical-pathological and genomic risk to guide adjuvant chemotherapy in node-negative breast cancer and provides more individualized information than clinical-pathological or genomic data alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.